T. Rowe Price Associates, Inc. 13D and 13G filings for Immuneering Corporation:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-04-10 12:58 pm Sale | 2024-03-31 | 13G | Immuneering Corporation IMRX | T. Rowe Price Associates, Inc. | 910,266 3.100% | -2,467,834 (-73.05%) | Filing |
| 2024-02-14 10:03 am Sale | 2023-12-31 | 13G | Immuneering Corporation IMRX | T. Rowe Price Associates, Inc. | 3,378,100 11.500% | -241,460 (-6.67%) | Filing |
| 2023-02-14 12:38 pm Purchase | 2022-12-31 | 13G | Immuneering Corporation IMRX | T. Rowe Price Associates, Inc. | 3,619,560 13.700% | 431,055 (+13.52%) | Filing |
| 2022-02-14 2:34 pm Purchase | 2021-12-31 | 13G | Immuneering Corporation IMRX | T. Rowe Price Associates, Inc. | 3,188,505 12.200% | 151,523 (+4.99%) | Filing |
| 2021-08-10 1:37 pm Purchase | 2021-07-31 | 13G | Immuneering Corporation IMRX | T. Rowe Price Associates, Inc. | 3,036,982 12.400% | 3,036,982 (New Position) | Filing |